TBL1XR1 mutations promoted tumor progression in diffuse large B-cell lymphoma through impairing nature killer cytotoxicity via the MYC-CD47/PD-L1 axis.
Certain lymphoma mutations trigger dual immune escape through CD47 and PD-L1, suggesting a rational combination therapy strategy for this subtype.
Using patient samples and cell line models, this Ruijin Hospital (Shanghai) study elucidates a novel resistance mechanism in TBL1XR1-mutant DLBCL, where transcriptional derepression of MYC drives simultaneous upregulation of CD47 and PD-L1, creating a dual immune evasion state that impairs NK cytotoxicity. This positions TBL1XR1 mutation as a biomarker for combined CD47 blockade + PD-1 checkpoint inhibitor therapy in a biologically defined DLBCL subset.
What the study was
- Study design
- preclinical_mechanistic
- Population
- DLBCL (diffuse large B-cell lymphoma)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Molecular Cancer
Why it surfaced
TBL1XR1 is recurrently mutated in DLBCL; CD47 blockade (magrolimab and others) is in active clinical development; this mechanism provides the first rational link between TBL1XR1 mutational status and immune checkpoint therapy response in DLBCL; opens patient selection hypothesis for basket trials.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.